Your browser doesn't support javascript.
Baricitinib for patients with severe COVID-19-time to change the standard of care?
Supady, Alexander; Zeiser, Robert.
  • Supady A; Department of Medicine III, Interdisciplinary Medical Intensive Care, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau 79106, Germany; Department of Cardiology and Angiology I, Heart Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau 79106, Germany; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany. Electronic address: alexander.supady@uniklinik-freiburg.de.
  • Zeiser R; Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau 79106, Germany.
Lancet Respir Med ; 10(4): 314-315, 2022 04.
Article in English | MEDLINE | ID: covidwho-1773857
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article